Background The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …

Mitigating preterm encephalopathy continues to be one of the greatest challenges in
perinatal medicine. Preterm encephalopathy is associated with high mortality, serious …

Objective To evaluate whether magnesium sulphate (MgSO (4)) given to women at risk of
very-preterm birth would be neuroprotective in preterm newborns. Patients and methods In …

Background: Magnesium sulfate (MgSO4) is proven to be a neuroprotectant which functions
to reduce the risk of cerebral palsy in premature infants, but the effects on the short-term …

Prematurity remains a proximate cause of infant morbidity and mortality. 1 Despite extensive
years of research and investment, limited gains have been made in preventing preterm birth …

Background Australian and New Zealand clinical practice guidelines, endorsed by the
NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at …

Cerebral palsy (CP) is the most common cause of motor disability in childhood. CP is a
complex disease characterized by aberrant control of movement or posture that is …

Background Magnesium sulphate is extensively used in obstetrics for the treatment and
prevention of eclampsia. A recent meta‐analysis has shown that magnesium sulphate is an …

The aim of the study was to identify the optimal therapeutic maternal magnesium drug
exposure and maternal serum concentration to prevent cerebral palsy in the extremely …

Background: Preterm birth is one that occurs at< 37 weeks of gestation or less than 258 days
of gestation. WHO classifies premature infants into three categories, Extremely preterm (< …